TransMedics Group (TMDX)
(Delayed Data from NSDQ)
$138.97 USD
-4.83 (-3.36%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $140.00 +1.03 (0.74%) 7:58 PM ET
1-Strong Buy of 5 1
F Value B Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$138.97 USD
-4.83 (-3.36%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $140.00 +1.03 (0.74%) 7:58 PM ET
1-Strong Buy of 5 1
F Value B Growth A Momentum B VGM
Zacks News
QGEN Stock Might Rise on Partnership With Bode for GEDmatch PRO
by Zacks Equity Research
QIAGEN announces exclusive global commercial partnership with Bode Technology. Per the agreement, Bode will manage all commercial transactions for QIAGEN's GEDmatch PRO globally.
Reasons to Retain Alcon Stock in Your Portfolio for Now
by Zacks Equity Research
Strong growth in the Surgical and Vision Care businesses raises investors' optimism for ALC.
STIM Stock Likely to Gain From Updated TMS Coverage
by Zacks Equity Research
Neuronetics announces that TMS coverage has been updated to reduce access barriers for patients with MDD. In line with this, BCBS and Louisiana Medicaid have expanded their TMS coverage.
TNDM Stock Likely to Gain From Innovation Amid Competition
by Zacks Equity Research
Tandem Diabetes is driving transformative innovation to help reduce the burden of diabetes and create new possibilities for people living with the condition.
EDAP's Avenda Deal for AI-Assisted Cancer Care Likely to Drive Stock
by Zacks Equity Research
When combined with EDAP's Focal One platform, Avenda's Unfold AI enables more accurate and patient-specific treatment options.
BiomX Stock Gains From Favorable Study Data Presentation on BX004
by Zacks Equity Research
PHGE is set to present data from its Phase 1b/2a study for BX004 at the North American Cystic Fibrosis Conference in Boston on Sept. 27 and Sept. 28.
VERO Stock Likely to Get Support From New Regulatory Nod in Australia
by Zacks Equity Research
The latest approval for Venus Concept in Australia reinforces its position as a global player in the aesthetic technology space.
Abbott Stock Hurt by Macroeconomic Issues & FX Headwind
by Zacks Equity Research
Foreign exchange fluctuation is a major headwind for ABT, as a considerable percentage of its revenues comes from outside the United States.
QGEN Stock Likely to Gain From Newly Launched Assays for QIAcuity
by Zacks Equity Research
QIAGEN launches 100 new assays for QIAcuity. The newly launched assays are now available through the company???s GeneGlobe platform.
Reasons to Retain EYE Stock in Your Portfolio for Now
by Zacks Equity Research
The strong execution of strategic initiatives and robust market expansion of the Owned and Host segment bode well for National Vision.
Is Teleflex Stock a Smart Option for Your Portfolio Right Now?
by Zacks Equity Research
TFX instils optimism with its robust performance in the Interventional category and potential in Asia.
BSX Gets FDA Nod on INGEVITY+ Pacing Lead in the LBBA: Stock to Gain?
by Zacks Equity Research
Boston Scientific received FDA approval on the expanded indication for INGEVITY+ Pacing Leads. Data demonstrated this lead to be safe and effective for LBBA pacing.
Is Phibro Stock Worth Retaining in Your Portfolio Now?
by Zacks Equity Research
PAHC Animal Health business, supported by the flourishing vaccine product line, drives optimism for future growth. However, macroeconomic impacts are a concern.
Labcorp Stock Gains From Its Latest Acquisition of BioReference Health
by Zacks Equity Research
LH completes the acquisition of BioReference Health, a wholly-owned subsidiary of OPKO Health. The acquisition includes BioReference Health's laboratory testing businesses.
QGEN Stock Likely to Gain From Innovation Amid Competition
by Zacks Equity Research
To support internal growth, QIAGEN invests heavily in research and development for the menu expansion of its key platforms.
DGX Stock Likely to Gain From Allina Health's Select Lab Assets Buyout
by Zacks Equity Research
With the completion of the acquisition, Allina Health's clinic physicians will now have access to Quest Diagnostics' laboratory services.
Should You Continue to Retain MYGN Stock in Your Portfolio?
by Zacks Equity Research
Myriad Genetics is advancing with strategic priorities, and bringing new products and upgrades to the market, positively influencing investors' sentiment.
Zacks.com featured highlights include TransMedics, Iamgold, Graham and GIII Apparel
by Zacks Equity Research
TransMedics, Iamgold, Graham and GIII Apparel have been highlighted in this Screen of The Week article.
KIDS Stock Gains From Its New Enabling Technologies Division Launch
by Zacks Equity Research
OrthoPediatrics recently launched its Enabling Technologies division, set to generate sustainable revenue growth and gain access to new markets and specialties beyond orthopedics.
4 Stocks Backed by High Efficiency for Solid Gains Amid Volatility
by Santanu Roy
Invest in stocks of TMDX, IAG, GHM and GIII to tap their high-efficiency levels.
CVS Stock Gains From Its Birth Control Prescribing Service Launch
by Zacks Equity Research
CVS Health announces that nearly 400 CVS Pharmacy locations in Massachusetts have started offering hormonal contraceptive prescribing services.
Labcorp Stock Gains From Market Expansion Efforts Amid Macro Woes
by Zacks Equity Research
LH is well-placed for long-term success in Cell & Gene Therapy, expanding into the consumer market and international growth through the specialty testing and biopharma business.
Sanara Stock Gains From New US Distribution Deal With ChemoMouthPiece
by Zacks Equity Research
SMTI, along with InfuSystem, inked a U.S. distribution agreement with ChemoMouthpiece. Under the agreement, ChemoMouthpiece's oral cryotherapy device will be distributed in cancer centers.
Should You Continue to Retain OMCL Stock in Your Portfolio Now?
by Zacks Equity Research
Omnicell is well-placed for growth in the upcoming quarters owing to its progress in achieving the Autonomous Pharmacy goal.
Paragon 28 Stock Gains From the Latest Launch of Its Right-Angle Drill
by Zacks Equity Research
FNA launched the Right-Angle Drill to enhance the APEX 3D Total Ankle Replacement System. The drill is designed to improve tibia preparation.